Must Read consensus statement on Embolic strokes of undetermined source EHJ Editor-in-Chief European Society of Cardiology Journals
academic.oup.com/eurheartj/arti…

✅ In the #ONCO_DVT trial, 12-month #edoxaban was superior to 3-month edoxaban for cancer-related distal #DVT , regardless of edoxaban dose. Read more with open-access in #EHJPharmacotherapy ➡️ bit.ly/onco-dvt
#DOAC #cancer #DVT

In this large, real-world study, GLP-1 RA use was not associated with a higher risk of HHF/CV death but with longer survival and less major CV adverse in patients with HF and T2DM
academic.oup.com/ehjcvp/article…
EHJ-CVP Editor-in-Chief Stefan Agewall Felice Gragnano

Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study academic.oup.com/ehjcvp/article…

EHJ-CVP Editor-in-Chief Stefan Agewall Felice Gragnano

De-escalation and short DAPT strategies are both important approaches to reduce post-PCI bleeding in clinical practice. A new #PharmaPulse is now online in #EHJPharmacotherapy bit.ly/3TMccW4

Felice Gragnano EHJ-CVP Editor-in-Chief Mattia Galli Eliano Navarese Francesco Costa #DAPT

Over the last three days, we’ve seen almost all pharmacological strategies presented at #ACC24 fail, including beta blockers, which seemed like the only certainty. On the contrary, if we are to believe in the results we've seen, we should start using more microaxial flow pump

How should #anticoagulants and #antiplatelet therapy be used in different clinical settings? Expert perspective from Stefan Agewall in #EHJPharmacotherapy editorial👉 bit.ly/3PRhaQl
Felice Gragnano EHJ-CVP Editor-in-Chief Mattia Galli SABOURETCardiologist #coronary #PCI #afib2024

#EHJPharmacotherapy best of: PATH-PCI trial. This is the largest (n=2237) RCT on guided selection of P2Y12 inhibiting therapy vs standard therapy in CCS. Guided therapy was associated w/ a 32% reduction in the net clinical benefit 180 days after PCI bit.ly/3Ix8kmD

#DAPT

Use of #PPI is associated with ⬆️ risk of out-of-hospital cardiac arrest in the general population: data from a nationwide 🇩🇰 study now published in #EHJPharmacotherapy 👉 bit.ly/3Tn1HIB

Diego Segura-Rodríguez SABOURETCardiologist Felice Gragnano EHJ-CVP Editor-in-Chief #OHCA #heartattack

DAPA-MI did not show benefit of early initiation of #SGLT2i on #MACE or HHF in low-risk MI patients. Why the discordance? Read more in #EHJPharmacotherapy 👉
academic.oup.com/ehjcvp/article…

Mattia Galli Felice Gragnano DoreenTan.CVPx European Society of Cardiology Journals European Society of Cardiology

#postMI #HFhospitalisation

Well done!! Italo Porto Domenico D'Amario Rocco Vergallo FRANCESCO BURZOTTA Antonio Maria Leone Stefano Migliaro Renzo Laborante

🫀 Switching from #DAPT to dual pathway inhibition in pts with chronic coronary syndrome: the SWAP-AC Study ⤵️

📖 DAPT associated with ⬆️ P2Y12 inhibition, DPI with ⬇️ thrombin generation

From TH current issue👉 thieme-connect.de/products/ejour…

#Platelets Luis Ortega Paz Mattia Galli

🔍A journey into the pleiotropic effects of ticagrelor in this elegant study exploring the effects of ticagrelor vs clopidogrel on ischemic preconditioning assessed by intracoronary-ECG: the TAPERS randomized study🎯bit.ly/3TeszdF

#EHJPharmacotherapy Ricky Turgeon PharmD

What is the best antithrombotic regimen after #TAVR ?
This updated network meta-analysis provides the comparative effects of different treatments🖥️ academic.oup.com/ehjcvp/advance…

Ricky Turgeon PharmD Arden Barry

#EHJPharmacotherapy #TAVI #Cardiox #cardiotwitter

Must-read debate on prophylactic stenting of vulnerable plaques eurointervention.pcronline.com/article/prophy…

The year in cardiovascular medicine 2023: the top 10 papers in thrombosis and antithrombotic treatment by academic.oup.com/eurheartj/arti…

This major RCT published in EHJ-CVP in 2020 represents an important piece of evidence in support of a guided selection of P2Y12i in CCS 🎯

The FLOW trial will shed light on the benefits of #semaglutide on the progression of renal impairment in pts with #T2DM and #CKD . A top-read #PharmaPulse article discusses the potential implications of this upcoming trial for practice: academic.oup.com/ehjcvp/article…
#EHJPharmacotherapy

Standard 12-month #DAPT is still the strategy of choice after #ACS
Should bleeding reduction strategies be the new standard of care? This #PharmaPulse explores Pros & Cons academic.oup.com/ehjcvp/advance…

Francesco Costa Eliano Navarese Mattia Galli
#EHJPharmacotherapy
#pharmacotherapy

DEB better than POBA for in-stent restenosis. Yet, the remaining 18% rate of adverse events with DEB underlines the need for further strutegies. jamanetwork.com/journals/jama/…